Search

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

COVID-19 & Hematology Information Center

Standing by hematology professionals in the COVID-19 crisis
 

Read more

Splenic marginal zone lymphoma study

An SWG Grant-supported project initiated by the EHA Lymphona Group.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Streamlining SoHO Management in EU Hospitals

The European Commission's Directorate-General for Health and Food Safety (DG SANTE) is committed to improving the management of Substances of Human Origin (SoHO) in EU hospitals.

Read more

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more